💊📦 BPOM Drug Import Review Steps: A Step-by-Step Guide for Indonesia

If you want to import medicines into Indonesia, you will quickly meet one acronym everywhere: BPOM (Badan Pengawas Obat dan Makanan), the Indonesian Food and Drug Authority. This guide walks you through how the BPOM drug import review process works in practice, so you can plan your market entry, avoid delays at customs, and stay compliant from day one.

📚 Quick Navigation

• BPOM Basics: Why Drug Import Approval Matters
• Key Laws and Regulatory Framework
• Step 1 – Prepare Your Legal Entity and Licenses
• Step 2 – Build a Complete Drug Registration Dossier
• Step 3 – Online Submission to BPOM and SKI Import Letter
• Step 4 – BPOM Technical Review and Evaluation
• Step 5 – Approval, NIE, and Import Clearance
• Step 6 – Post-Market Surveillance and Ongoing Obligations
• Special Access and Exceptions for Imported Drugs
• Common Mistakes and How to Avoid Them
• BPOM vs. Other Drug Regulators (Quick Comparison)
• FAQ: BPOM Drug Import Review
• Contact Foundersbacker

1. BPOM Basics: Why Drug Import Approval Matters

Indonesia is the largest pharmaceutical market in Southeast Asia, and demand for imported drugs and biologics continues to grow. Before any of these products can be sold locally, they must pass BPOM’s review and obtain both a valid distribution license and an import permit. In simple terms, if BPOM has not approved your product, it cannot legally enter the market, appear on pharmacy shelves, or be used in hospitals, even if it is already approved in the EU, US, or other ASEAN countries.

BPOM’s mandate is to protect public health by ensuring that every drug circulating in Indonesia is safe, effective, and produced according to Good Manufacturing Practice (GMP). For foreign companies, that means your local partner – not the overseas manufacturer – will usually hold the registration, be responsible for submissions, and act as the official point of contact with the regulator.

2. Key Laws and Regulatory Framework

The BPOM drug import review is not an isolated process. It is anchored in a broader health and trade regulatory framework. At a high level, several layers of regulation interact:

• National health laws that define safety, quality, and efficacy requirements for medicines and traditional remedies.
• BPOM regulations and guidelines that cover classification, labeling, registration procedures, and post-market surveillance.
• Ministry of Health (MoH) rules governing pharmaceutical manufacturing licenses and pharmaceutical wholesalers (PBF).
• Trade and customs rules that require an Importer Identification Number (API) and Letters of Import (SKI) before goods can clear customs.

For practical purposes, your regulatory roadmap should integrate all of these: company setup, licensing, BPOM product registration, and import permits. Skipping any one of them almost guarantees delays or rejections at the border.

3. Step 1 – Prepare Your Legal Entity and Licenses

The first step is deciding who will actually hold your drug registrations in Indonesia. Foreign manufacturers cannot usually register products directly with BPOM. Instead, you must appoint a local company – a PT PMA subsidiary, local pharmaceutical company, or licensed distributor – to act as the Marketing Authorization Holder (MAH) and importer.

Your chosen local entity typically needs to:

• Have a valid Business Identification Number (NIB), which also acts as the Importer Identification Number (API) through the national OSS online system.
• Hold the relevant pharmaceutical industry license or a Pharmaceutical Wholesaler License (PBF), depending on the role (manufacturer vs. importer/distributor).
• Maintain appropriate storage facilities and quality systems that comply with Good Distribution Practice (GDP).

At this stage, you should also put in place a clear commercial agreement between the foreign manufacturer and the local partner, as BPOM communications, safety reporting, and recall responsibilities will all flow through the registration holder.

4. Step 2 – Build a Complete Drug Registration Dossier

Once your local entity and licenses are in order, the next task is preparing a complete dossier for each product you want to import. BPOM follows a risk-based approach and expects documentation that demonstrates quality, safety, and efficacy. For imported drugs, a typical dossier includes:

• Administrative documents – power of attorney, letter of appointment, import responsibilities, and proof of company licenses.
• Quality documents – full formulation, manufacturing process, specifications, stability data, and Certificates of Analysis.
• Non-clinical and clinical data – pre-clinical toxicity and pharmacology, clinical trial data, or literature justifying efficacy and safety.
• GMP certificates from the country of origin and inspection reports from competent authorities.
• Labeling and packaging drafts in Bahasa Indonesia, including dosage, indications, warnings, and storage instructions.

Investing in a well-structured dossier pays off later. Many delays during BPOM review come from missing documents, inconsistent data between different sections of the file, or labels that do not fully match the approved indications and dosage forms.

5. Step 3 – Online Submission to BPOM and SKI Import Letter

With the dossier ready, the local registration holder submits the application through BPOM’s online systems. Depending on the product category – such as prescription medicines, OTCs, biologics, or traditional medicines – different portals and forms may be used, but the logic is similar: enter product data, upload documents, and pay the registration fees electronically.

For the physical import of finished products, BPOM also issues a Surat Keterangan Impor (SKI), or Letter of Import. This SKI is linked to specific shipments and is required by customs before your drugs are released into Indonesia. In practice, you will often need to coordinate timing between obtaining product registration (NIE), SKI issuance, and customs clearance to avoid your goods sitting too long at the port.

6. Step 4 – BPOM Technical Review and Evaluation

After submission, BPOM performs an administrative check to ensure the file is complete. If anything important is missing, the application may be put on hold while your local entity uploads corrections. Once administratively accepted, the dossier moves to technical review.

During technical review, BPOM experts assess:

• Whether the clinical and non-clinical data support the claimed indications and dosage.
• Whether the formulation and manufacturing process comply with quality standards.
• Whether labels and patient information leaflets are clear, accurate, and in Bahasa Indonesia.

BPOM may also request laboratory testing of samples, especially for high-risk categories or new active substances. Typical timelines can range from a few months to more than a year, depending on product complexity, registration category, and how quickly you respond to BPOM’s questions.

7. Step 5 – Approval, NIE, and Import Clearance

If BPOM is satisfied that the drug meets all requirements, it issues a marketing authorization in the form of a Nomor Izin Edar (NIE) – a distribution license number that must appear on your packaging. The validity period is usually several years, after which renewal is required if you want to keep importing and selling the product.

With an active NIE, every shipment of your drug must still obtain SKI approval and comply with customs procedures. BPOM and customs systems are increasingly integrated, so inconsistencies between registered data (e.g., dosage form, strength, manufacturer) and the import declaration can trigger delays, inspections, or even rejection at the border.

8. Step 6 – Post-Market Surveillance and Ongoing Obligations

BPOM’s role does not end at approval. The agency operates a post-market surveillance system to track safety signals, verify labeling compliance, and ensure that imported drugs continue to meet quality standards. Your local registration holder must be ready to:

• Report adverse drug reactions and serious safety issues within specified timelines.
• Cooperate with BPOM inspections of warehouses and distribution channels.
• Implement recalls or corrective actions if BPOM identifies quality or safety problems.
• Renew the NIE before expiry and notify BPOM of any changes in formulation, manufacturing site, labeling, or ownership.

In practice, this means treating BPOM compliance as an ongoing program, not a one-off project. Align your pharmacovigilance, quality assurance, and regulatory teams so they can respond quickly to BPOM requests and market incidents.

9. Special Access and Exceptions for Imported Drugs

Not every imported drug requires a full commercial distribution license. Indonesian regulations allow limited import of certain products for tightly defined purposes. Examples include medicines for personal use, clinical trials, research and development, donations, government programs, or urgent national needs where no local alternatives exist.

Even in these special cases, imports usually require prior BPOM approval, specific documentation, and proof that products will not be sold commercially. Quantities are strictly limited, and shipments often move under special access schemes with enhanced oversight at customs. Companies should therefore treat these routes as complementary – not substitutes – for full registration when planning a long-term Indonesian strategy.

10. Common Mistakes and How to Avoid Them

Many delays in BPOM drug import review are avoidable. Below are common pitfalls and practical tips:

• Choosing the wrong local partner – Work with a company that understands pharmaceutical regulations, not just a general importer.
• Incomplete dossiers – Double-check administrative documents, GMP certificates, and laboratory data before submission.
• Weak labeling in Bahasa Indonesia – Poor translations or missing warnings are frequent reasons for questions from BPOM.
• No internal owner – Assign a dedicated regulatory project manager who coordinates between HQ, the manufacturer, and the local partner.
• Ignoring renewal timelines – Track NIE expiry dates well in advance so your license does not lapse while products are still in the market.

Taking a systematic, project-managed approach can significantly shorten your time to market and reduce the risk of expensive product holds at the border.

11. BPOM vs. Other Drug Regulators (Quick Comparison)

For global pharmaceutical companies, it is helpful to see how BPOM compares with other major drug regulators. The table below summarizes a few high-level similarities and differences. It is not exhaustive, but it gives a quick orientation when planning multi-country registrations.

Aspect	Indonesia – BPOM	United States – FDA	European Union – EMA
Who can hold the registration?	Local Indonesian entity (manufacturer, PBF, or authorized representative) acts as holder of product registration.	US-based company or US agent holds the NDA/ANDA or biologics license.	Marketing authorization holder established in the EU/EEA.
Scope of products	Medicines, traditional medicines, biologicals, supplements, certain medical devices, food, and cosmetics.	Human and veterinary medicines, biologics, medical devices (through FDA’s device centers), food, and cosmetics.	Centralized procedure covers innovative human and veterinary medicines and certain biologics; national agencies handle others.
Import permit for finished drugs	Requires SKI Letter of Import issued by BPOM for each shipment, in addition to NIE license.	No separate SKI-style import approval, but FDA may detain products that appear non-compliant.	EU customs consult national authorities; no single EU-wide SKI but products must match approved marketing authorization.
Typical review timeline	Several months to over a year, depending on product type and dossier quality.	Standard review around 10–12 months for new drugs; priority pathways can be faster.	Centralized procedure typically up to 210 active days of EMA review, plus clock stops for questions.
Post-market obligations	Pharmacovigilance reporting, periodic safety updates, quality investigations, recalls, and renewal of NIE.	Risk management plans, safety reporting, inspections, periodic reports.	EMA-wide safety monitoring plus national-level pharmacovigilance and inspections.

While each regulator has its own terminology and systems, the underlying expectations – strong quality systems, complete data, and proactive safety monitoring – are very similar.

12. FAQ: BPOM Drug Import Review

Q1. How long does BPOM drug import approval usually take?

Timelines vary. Simple, well-documented products may be approved within several months, while new active substances or complex biologics can take considerably longer. The quality of your dossier, the responsiveness of your local partner, and whether BPOM requests additional lab testing all influence the total time to approval.

Q2. Can a foreign company hold the BPOM registration directly?

No. Foreign manufacturers cannot normally hold BPOM product registrations in their own name. You must appoint an Indonesian legal entity – either your own subsidiary or a trusted local partner – to act as the Marketing Authorization Holder, manage communication with BPOM, and be legally responsible for the product in Indonesia.

Q3. Do I always need a full distribution license if I only import small quantities?

For commercial sales, a valid distribution license and full BPOM registration are mandatory regardless of volume. Limited exceptions exist for personal use, research, clinical trials, donations, or urgent national needs, but these require specific approvals and are tightly controlled. If you plan to build a long-term business, you should treat full registration as the default route.

📨 Contact Foundersbacker

🌍 Sustainability is the future—are you part of it?
At Foundersbacker, we help businesses go beyond cost-cutting by unlocking new revenue streams through green innovation.
🔥 Our Angel Syndicate is launching! Now, anyone can become an angel investor in the green revolution. Get in touch and seize this opportunity!
📩 Arthur Chiang

Email: arthur@foundersbacker.com
Mobile: +886 932 915 239
WhatsApp: Chat on WhatsApp

🔔 Subscribe to Foundersbacker LinkedIn Newsletter 🌐 Visit Foundersbacker Official Website